News | July 19, 2007

Boston Scientific Falls Short of Projected $150M in Q207

July 20, 2007 – Despite forecasts by analysts at Thomson Financial that Boston Scientific Corp. would earn $150 million in the second quarter of this year, the company came up short at $115 million in the second quarter, or 7.7 cents a share, due to a significant sales slump in implantable defibrillators and coronary stents.
In 2006, Boston Scientific reported a $4.3 billion loss from its April 2006 purchase of Guidant Corp. Excluding special charges related to the acquisition, the company's profit fell 56 percent from the second quarter of 2006.

Related Content

Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered stent system, which has been on the market for twenty years and recently received premarket approval for treatment of iliac arterial occlusive disease
News | Stents
Getinge Enters into Commercial Distribution Agreement with Cook Medical for iCast Covered Stent System in the United States

April 17, 2024 — Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered ...

Home April 17, 2024
Home
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
News | Stents
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
This study aims to compare the GORE VIABAHN VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this condition
News | Stents
First Patients Enrolled in the Gore VBX Forward Clinical Study

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
Study to enroll 15 acute stroke patients across three U.S. sites
News | Stents
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions for Use (IFU) do not adequately address precautions to take when treating patients who have undergone transcatheter aortic valve replacement (TAVR)
News | Stents
Abiomed Recalls All Impella Left Sided Blood Pumps for Risk of Motor Damage After Contact with Transcatheter Aortic Valve Replacement (TAVR) Stent

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
The Gore VBX FORWARD Clinical Study aims to compare the VBX Stent Graft primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease
News | Stents
Gore Initiates Study to Compare the Gore Viabahn VBX Balloon Expandable Endoprosthesis to Bare Metal Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents in all diseased arteries was found to be as safe and effective at one year of follow-up as staged treatment, according to findings from the first large, randomized trial to address this question that is being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.
News | Stents
Immediate Complete Revascularization as Safe and Effective as Staged Procedure in Treating Multi-Vessel Disease

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
A study of more than 100,000 patients has revealed that, for patients with blockages in multiple arteries, those who opt for coronary artery bypass grafting (CABG) are less likely to die from their condition, less likely to need additional surgery, and less likely to have a heart attack than patients who choose to undergo a stent procedure.
News | Stents
Patients with Multiple Artery Blockages Undergoing Coronary Artery Bypass Surgery Fare Better, Live Longer than Those Who Opt for Stenting

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

Home January 23, 2023
Home
BIO-RESORT: TLF at five years
News | Stents
Favorable Outcomes for Orsiro DES presented at EuroPCR in the Five-Year BIO-RESORT Small Vessels Subgroup Analysis

July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...

Home July 05, 2022
Home
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.
News | Stents
FDA Class 1 Recall on iCast Stent for Separation Risk That May Cause Harm

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now